 |
Kurome Therapeutics
Last updated: October 06, 2024
Jan Rosenbaum, CEO
USA | Funding: $15M (+)
Website: https://kurometherapeutics.com/
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. The first goal is to to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms.
Website: https://kurometherapeutics.com/
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. The first goal is to to treat acute myeloid leukemia (AML) by targeting adaptive resistance mechanisms.
